Why Is PDEX Stock Rising Today? Pro-Dex Surges After Q4 Earnings Beat

Pro-Dex (PDEX) shares rose 22. 27% in intraday trading Thursday after the medical device manufacturer reported fiscal 2026 fourth-quarter earnings that significantly beat analyst expectations on every major metric.

Why is PDEX stock moving today? The Irvine-based company posted Q4 diluted EPS of $0.87 versus a $0.67 consensus — a roughly 30% beat — alongside net sales of $20.4 million, up 17% year-over-year and $1.2 million above estimates. Gross margin expanded sharply to 35% from 20% in the prior-year quarter.

What Did The Company Report?

The fourth-quarter results were the capstone of a strong fiscal 2026. Net sales of $20.4 million represented a $2.9 million increase from $17.5 million a year earlier. Gross profit more than doubled, rising 103% to $7.1 million from $3.5 million, while operating income surged 163% to $3.5 million from $1.3 million. Net income came in at $2.9 million, or $0.87 per diluted share, compared to $1.2 million, or $0.36, in the year-ago quarter.

Full-year results were equally impressive. Revenue grew 16% to $77.5 million from $66.6 million, driven by a $15.3 million increase in revenue from the company's largest customer. Full-year net income jumped to $13.7 million, or $4.12 per diluted share, from $9.0 million, or $2.67. Operating income increased 22% to $13.0 million.

The gross margin expansion stands out as the quarter's most notable figure. At 35%, it was 15 percentage points above the prior-year level. Management attributed the improvement to favorable product mix, better absorption of indirect manufacturing costs, and margin contributions from Advanced Precision Machining, LLC, which Pro-Dex acquired in February.

The dramatic margin shift ties back to a specific product transition. During most of Q4 fiscal 2025, Pro-Dex was shipping a legacy handpiece to its largest customer. The customer released a product hold on the next-generation version late in that quarter, and Pro-Dex resumed production and shipment of the new, higher-margin product. That transition was the primary driver of both the top-line and bottom-line improvement.

Why Did Investors React?

The earnings beat was comprehensive — across EPS, revenue, and margins — which is what pushed the stock higher. Still, the margin expansion appears to be the headline story. A jump from 20% to 35% gross margin signals a meaningful structural shift, not just one-time cost savings. The next-generation handpiece carries a better cost structure, and that margin profile could persist if volumes hold.

The APM acquisition added another layer. The subsidiary brought in $718,000 in revenue since the February close and contributed favorably to margins. For a micro-cap company with a market capitalization around $207 million, even a small acquisition that adds margin capacity can shift how investors value the business.

Put differently, the combination of product mix improvement and acquisition-driven margin contribution gives the results forward-looking weight beyond a single quarter.

That said, customer concentration remains a risk. The $15.3 million full-year revenue increase from a single customer highlights Pro-Dex's dependence on one medical device OEM. The $349,000 allowance for uncollectible receivables in Q4 adds another data point worth tracking.

The stock's broader trajectory provides additional context. PDEX shares have gained roughly 88% this year, and today's move extends that rally.

What Comes Next?

The next earnings call is scheduled for October 29, 2026, when executives will discuss Q1 fiscal 2027 results. Investors will want to know how much of the Q4 margin expansion was repeatable as the next-generation handpiece moves from ramp-up to steady state.

The $349,000 receivables allowance — the first of its kind in recent quarters — deserves a follow-up. Management explained it as a credit provision, but investors will want clarity on whether it reflects a one-off customer issue or a broader collections trend.

Operating expenses increased to $3.6 million from $2.2 million year-over-year, driven by a $349,000 receivables allowance, $436,000 in APM administrative costs, $500,000 in non-recurring consulting fees paid to APM's founder, and higher personnel costs. The integration of APM and the normalization of spending will be a storyline through fiscal 2027.

With the company's cash position at $8.2 million versus $419,000 a year ago, liquidity is strong. Pro-Dex's CEO noted the company continues to invest in growth and share repurchases, which could support the stock if the next-gen handpiece volume trajectory holds. Still, after a 22% single-session move, near-term volatility is a fair expectation as the market digests the full scope of the results.